Sarclisa Uniunea Europeană - română - EMA (European Medicines Agency)

sarclisa

sanofi winthrop industrie - isatuximab - mielom multiplu - agenți antineoplazici - sarclisa is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi) and have demonstrated disease progression on the last therapy. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.

SARCLISA 20 mg/ml România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

sarclisa 20 mg/ml

sanofi-aventis deutschland gmbh - germania - isatuximabum - conc. pt. sol. perf. - 20mg/ml - alte antineoplazice anticorpi monoclonali